Clinical Insights, Research and Collaboration in Theranostics
Theranostics is one of the fastest-evolving areas of precision medicine, bringing together advances in molecular imaging, radiopharmaceutical science, nuclear medicine, oncology and targeted therapies.
This section has been developed to support clinicians, researchers and healthcare professionals seeking to better understand the current role of theranostics, explore emerging evidence and stay connected with developments across the field.
Whether you are actively involved in theranostic practice or simply looking to expand your understanding, this hub provides access to educational content, research updates, expert perspectives and opportunities for collaboration.
CLINICAL OVERVIEW
Introduction to Theranostics
Theranostics combines diagnostic imaging and targeted radiotherapy through a shared biological target, supporting a more personalised approach to disease assessment and treatment.
The field continues to evolve rapidly across multiple disease areas, particularly within oncology, where theranostic approaches are already established in selected settings including prostate cancer, neuroendocrine tumours, thyroid cancer and non-melanoma skin cancer.
Advances in molecular imaging, radiopharmaceutical development and precision medicine continue to expand both clinical applications and research opportunities.
Areas of Interest:
-
Precision oncology
-
Molecular imaging
-
Radioligand therapy
-
Nuclear medicine
-
Radiopharmaceutical science
-
Personalised medicine
Clinical Guidelines & Best Practice
As theranostics continues to evolve, clinical practice is increasingly informed by a combination of published evidence, expert consensus, professional society recommendations and disease-specific treatment guidelines.
While there is currently no single global guideline that encompasses all aspects of theranostics, a growing number of organisations have published guidance relating to molecular imaging, radioligand therapy, nuclear medicine practice and specific disease applications. These resources help support patient selection, treatment planning, safety considerations and multidisciplinary care.
Healthcare professionals should always consider local regulatory requirements, institutional protocols and relevant disease-specific guidance when making clinical decisions.
Professional Resources
The following organisations provide valuable resources, guidelines, educational materials and updates relevant to theranostics and precision medicine:
-
European Association of Nuclear Medicine (EANM)
Visit >>
-
Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Visit >>
-
International Centres for Precision Oncology Foundation (ICPO)
Visit >>
-
International Atomic Energy Agency (IAEA)
Visit >>
-
Australian and New Zealand Society of Nuclear Medicine (ANZSNM)
Visit >>
-
Cancer Australia
Visit >>
-
National Comprehensive Cancer Network (NCCN)
Visit >>
-
European Society for Medical Oncology (ESMO)
Visit >>
As the evidence base continues to expand, Oncothera Advocacy will monitor and share significant developments, consensus recommendations and emerging best-practice considerations relevant to the theranostics community.
CLINICAL RESEARCH
Trials & Innovation
As an independent advocacy organisation, Oncothera provides a platform for the exchange of ideas, experiences and expertise. We believe that collaboration between patients, clinicians, researchers, industry and government is essential to ensuring the continued growth and responsible development of theranostics.
Through our Advocacy & Insights section, events, surveys and collaborative initiatives, we will continue to share expert perspectives, community feedback and emerging themes that influence the future of precision medicine.
Innovation remains central to the future of theranostics.
Researchers around the world continue to investigate new biological targets, radionuclides, imaging agents and treatment approaches across a growing number of disease areas.
Current areas of investigation include:
-
Targeted alpha therapies
-
Novel radioligands
-
Combination therapies
-
Earlier intervention strategies
-
Expanded disease applications
-
Personalised treatment pathways
The evidence base supporting theranostics continues to grow.
Clinical trials, translational research and real-world evidence studies are helping to improve understanding of treatment outcomes, patient selection, safety profiles and emerging therapeutic targets.
This section will feature:
-
Key publications
-
Research summaries
-
Emerging evidence
-
Clinical developments
-
Real-world experience
CLINICAL CONNECTIONS
Conferences & Events
Conferences, educational forums and scientific meetings play an important role in advancing knowledge and collaboration across the theranostics community.
Oncothera Advocacy actively participates in and supports initiatives that bring together clinicians, researchers, industry, policymakers and patient advocates, including:
-
Scientific congresses
-
Educational workshops
-
Webinars
-
Roundtable discussions
-
Research forums
-
Advocacy initiatives
View past and upcoming conferences, educational activities and opportunities to connect with the broader theranostics community.
Expert Commentary & Community Consultation
As the theranostics landscape continues to evolve, informed discussion and stakeholder engagement are becoming increasingly important.
Oncothera Advocacy actively participates in conversations that help shape the future of theranostics, bringing together perspectives from patients, healthcare professionals, researchers, industry, policymakers and advocacy organisations.
Through events, educational initiatives, surveys, roundtable discussions and stakeholder engagement activities, we seek to encourage meaningful dialogue around awareness, access, innovation and the future direction of theranostic medicine.
Contributing to the Conversation
Oncothera Advocacy supports opportunities for:
-
Expert commentary and thought leadership
-
Community and stakeholder consultation
-
Healthcare policy discussions
-
Access and equity conversations
-
Workforce and capability development
-
Research and innovation priorities
-
Patient-centred perspectives
By engaging with diverse stakeholders across the healthcare ecosystem, we aim to help identify opportunities, challenges and areas for future collaboration.
Interested in collaborating with Oncothera Advocacy?
Collaboration Opportunities
Progress in theranostics depends on collaboration. Researchers, clinicians, healthcare organisations, universities, industry partners and advocacy groups all play a role in advancing awareness, evidence generation and patient access.
Oncothera Advocacy seeks to facilitate meaningful connections across the theranostics ecosystem by supporting initiatives that encourage education, dialogue and shared learning.
Areas of collaboration may include:
-
Research initiatives
-
Educational programmes
-
Conference activities
-
Community engagement
-
Advocacy projects
-
Stakeholder partnerships
We welcome opportunities to collaborate with organisations and individuals who share a commitment to advancing theranostics and improving patient outcomes.
We invite healthcare professionals, researchers, institutions and organisations to connect with us to explore opportunities for partnership, education and community engagement.
Continue Exploring
Medical Disclaimer
The information provided on this website is intended for educational purposes only and should not be considered medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals who can consider individual circumstances and clinical needs.